What's New
News
FDA Announcement on ALS Drug Reflects Growing Hope for Treatments
The FDA’s recent approval of a new drug to treat ALS signals important and promising developments for…
AFTD Pleased to Announce New Brand Ambassador Nicole Petrie
ADTD is pleased to announce an official partnership with Nicole Petrie, a social media influencer and AFTD…
AFTD Ambassador Highlights Difficulties in Getting an FTD Diagnosis
AFTD Ambassador Deb Scharper shared the difficulties that she faced trying to get an accurate FTD diagnosis…
How to Support AFTD’s Mission through Your Workplace
AFTD’s volunteers and donors are essential to advancing our mission. Each contribution of time and funds provides…
“Chasing Rainbows” Play Debuts in Portland, Raises Funds for AFTD’s Mission
Stage actor Bob Powers debuted his one-person play Chasing Rainbows: A Story of Love, Loss, and Finding…
Dr. Bruce Miller Discusses bvFTD and Differences Between FTD Variants in Podcast Appearance
Bruce Miller, MD, discussed behavioral variant frontotemporal degeneration as well as the differences between different FTD variants…
In-Progress Clinical Trial Evaluating Speech Therapy for People with PPA
The Communications Bridge 2 clinical trial is currently evaluating whether a specially developed speech therapy regimen could…
Passage Bio Issues First Dose in FTD Gene Therapy Trial
Passage Bio, a company that specializes in developing genetic therapies, administered the first dose in a clinical…
Newspaper Editor Writes About Wife’s PPA Journey
Earlier this year, Blake Ovard, an AFTD volunteer and editor for the Hobbs News-Sun newspaper in New…
Ten Years of NAPA: Ensuring That Families Facing FTD Have a Seat at the Table
The National Plan to Address Alzheimer’s Disease marked its 10th anniversary in 2022, and AFTD has consistently…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)